News + Resources
Keep up with the latest
Featured
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
All Stories
News
Sanofi pays Scribe $25M to access CRISPR tools, writing new chapter in its NK cell therapy story
September 27, 2022
Fierce Biotech
Read Now
Press Release
Sanofi pays Scribe $25M to access CRISPR tools, writing new chapter in its NK cell therapy story
September 27, 2022
Fierce Biotech
Read Now
News
CEO of Doudna spinout: Within five years, genome editors will have a 'really big impact' on patients' lives
August 12, 2022
Endpoints News
Read Now
Press Release
CEO of Doudna spinout: Within five years, genome editors will have a 'really big impact' on patients' lives
August 12, 2022
Endpoints News
Read Now
News
Scribe Therapeutics converting an Alameda shipway into a lab
July 30, 2022
The Real Deal
Read Now
Press Release
Scribe Therapeutics converting an Alameda shipway into a lab
July 30, 2022
The Real Deal
Read Now
Press Release
Scribe Therapeutics Announces Expansion of San Francisco Bay Area Headquarters, 3 Key Senior Hires
July 26, 2022
Read Now
Press Release
Scribe Therapeutics Announces Expansion of San Francisco Bay Area Headquarters, 3 Key Senior Hires
July 26, 2022
Read Now